Copyright
©The Author(s) 2017.
World J Clin Cases. Aug 16, 2017; 5(8): 307-323
Published online Aug 16, 2017. doi: 10.12998/wjcc.v5.i8.307
Published online Aug 16, 2017. doi: 10.12998/wjcc.v5.i8.307
Name of drug | Routes and dosages | Adverse effects | Recommendations for use | Mechanism of action |
Morphine[12,22] | Intrathecal: 100-200 μg | Pruritus | Useful in neuraxial blocks | |
Epidural: 1-5 mg | Nausea vomiting | Not recommended for peripheral nerve blocks | ||
Peripheral nerve block: 75-100 μg/kg | Respiratory failure | |||
Fentanyl[23-26,30-35] | Intrathecal: 10-25 μg | Same adverse effects as morphine | Useful in neuraxial blocks | |
Epidural: 2-4 μg/mL | Adverse effect profile slightly favourable in neuraxial use | Not recommended in neuraxial blocks due to inconsistent results | ||
Peripheral nerve block | Increased sedation, bradycardia and hypotension | Spinal opioid receptor | ||
Sufentanyl[36-40] | Intrathecal: 1.5-5 μg | Efficacious in neuraxial blocks | Local action in peripheral nerve blocks | |
Epidural: 0.75-1.0 μg/mL | ||||
Not used in peripheral nerve blocks | ||||
Hydromorphone[41-44] | Intrathecal: 100 μg | Better adverse effect profile than Morphine | Useful in neuraxial blocks | |
Epidural: 500-600 μg | ||||
Not used in peripheral nerve blocks | ||||
Buprenorphine[5,45-48] | Intrathecal: 75-150 μg | Good efficacy in neuraxial and peripheral nerve block routes | ||
Epidural: 150-300 μg | ||||
Peripheral nerve block: 300 μg | ||||
Tramadol[49-72] | Intrathecal: 10-50 mg | Nausea and vomiting | Present evidence supports use in epidural infusions | Weak opioid agonist actions |
Epidural: 1-2 mg/kg | Poor evidence in peripheral nerve block studies | Sodium/potassium channel blocking actions | ||
Peripheral nerve block: 1-5 mg/kg | Blockade of norepinephrine and serotonin uptake | |||
Clonidine[89-121] | Intrathecal: 15-40 μg | Sedation | Good quality evidence to support use in neuraxial blocks especially at lower dosages | Activation of post junctional alpha-2 receptors in dorsal horn of spinal cord |
Epidural: 25-50 μg | Bradycardia | In PNB prolongs block with Bupivacaine but poor efficacy with Ropivacaine and levobupivacaine | ||
Peripheral nerve block: 0.5-5 μg/kg (150 μg is the maximum allowed dose in PNB) | Hypertension | Additional benefit in Alcohol withdrawal | ||
Adverse effects show association with dose | ||||
Dexmeditomidine[122-147] | Intrathecal: 5-10 μg | Sedation | Prolongation of neuraxial and peripheral nerve blocks with good efficacy of use | Mechanism similar to Clonidine |
Epidural: 1 μg/kg | Bradycardia | |||
Peripheral nerve block: 20-150 μg | Hypertension | |||
Adverse effects show association with dose | ||||
Dexamethasone[148-161] | Intrathecal: 8 mg | Adverse effects minimal | Efficacious in neuraxial blocks, however better studies required | Local action on nerve fibers |
Epidural: 4-8 mg | Advantageous to prevent ponv | Prolongs nerve blockade in PNB | ||
Peripheral nerve block: 1-8 mg | Troublesome paresthesias with PNB use | |||
Midazolam[164-184] | Intrathecal: 1-2.5 mg | Sedation | Neurotoxicity is a major concern in neuraxial and peripheral nerve routes | GABAergic and opioid receptor mechanisms |
Epidural: 50 μg/kg diluted in 10 mL of saline | Respiratory depression | Not recommended for routine neuraxial and PNB use | ||
Neostigmine[185-202] | Intrathecal: 5-10 μg to 50-150 μg | Neuraxial use associated with bradycardia, restlessness | Lower dosages recommended for neuraxial use | Enhancement of endogenous acetylcholine at nerve terminal |
Epidural: 1, 2 and 4 μg | PNB use associated with gastrointestinal adverse effects | Not recommended for PNB use (neurotoxicity in animal models) | ||
Peripheral nerve block-not investigated | ||||
Ketamine[203-223] | Neuraxial use associated with nausea, vomiting and hallucinations | Neuraxial use-shortens onset and duration of anesthesia | NMDA receptor antagonists shown to have local anesthetic properties | |
PNB use associated with psychomimetic sequelae | Not recommended for PNB use | Cholinergic, adrenergic and 5HT mechanisms | ||
Magnesium[224-238] | Intrathecal: 25-100 mg | Headache | Prolongs analgesia and quality of block by all perineural routes | NMDA receptor antagonism |
Epidural: 50-100 mg | Cardiovascular disturbances | However more studies required to determine minimal effective doses | Voltage gated calcium channel blockade | |
Nausea vomiting | Not recommended for routine use |
- Citation: Swain A, Nag DS, Sahu S, Samaddar DP. Adjuvants to local anesthetics: Current understanding and future trends. World J Clin Cases 2017; 5(8): 307-323
- URL: https://www.wjgnet.com/2307-8960/full/v5/i8/307.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v5.i8.307